Post-earnings recap
Reported
Wed, Feb 2, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
Boston Scientific's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock dropped 4.74%, likely reflecting investor concerns about ongoing supply chain challenges and the lack of revenue data. The absence of guidance may also have contributed to the negative market reaction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.45 | N/A | +3.21% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the impact of external factors on performance. They remain focused on long-term growth strategies.
Management highlighted ongoing challenges in the supply chain.
They emphasized a commitment to innovation despite market pressures.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—